ANATOMY OF THE SHORT TERM $GENZ (GENZYME) TRADE
Stock price of Genzyme spiked on the news that FDA granted approval to Lumizymethel (aglucosidase alfa) for the treatment of late onset Pompe disease. Pompe disease is a rare and often fatal condition that disables the heart and muscles due to deficiency of an enzyme called alpha-glucosidase (GAA). Lumizyme, marketed outside the US as Myozyme is approved for the treatment of Pompe disease in about 45 countries and is available in the US for the treatment of infants and children.
Approval of Lumizymethe was expected on Jun 17, 2010. The only surprise was that the approval came about three weeks early. … Please click here or the title below to read more.
May 29, 2010